retatrutide obesity trial results Lilly's triple agonist achieves 16.8% weight loss in phase 3 Retatrutide produces up to 30.3%

And while that might mean (temporarily) retiring a favourite hand cream or tweaking your grocery list, its yet another reminder to appreciate our sense of smell an invisible but powerful part of everyday life.

Clinical trials demonstrate that GLP-1 agonists lower blood pressure, improve lipid profiles, and reduce heart attack and stroke risk independent of weight loss alone

The products used in our program are formulated to protect lean muscle mass and to use fat stores as fuel, thereby eliminating these risks

Several additional GLP-1 receptor agonists also display neuroprotective properties in preclinical AD models

You can do our Biohackr Benchmark Program to do a deep dive into your genetics, catrdiac risk, lipid profile, insulin sensitivity, hormone levels and more to get a whole body picture of where you are, what your risks are, and what therapies may be best to optimize YOU.

And like many medications, Ozempic can cause side effects